middle.news
How Will Arovella’s $3.21M R&D Rebate Accelerate ALA-101 Trials?
9:20am on Tuesday 23rd of September, 2025 AEST
•
Biotechnology
Read Story
How Will Arovella’s $3.21M R&D Rebate Accelerate ALA-101 Trials?
9:20am on Tuesday 23rd of September, 2025 AEST
Key Points
Received $3.21 million R&D tax incentive refund for FY2025
Funds strengthen cash position ahead of clinical trials
ALA-101 targets CD19-positive lymphoma and leukemia
IND application to be lodged with FDA within 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE